Cholesterol-lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial.

Added 807 days ago (24.05.2020)
Authors: Broch K, Gude E, Karason K, Dellgren G, Rådegran G, Gjesdal G, Gustafsson F, Eiskjaer H, Lommi J, Lemström KB, Andreassen AK, Gullestad L
PubMed id: 32445429
Read article